Of the nine transcription factors, six (ZBTB33, YY1, TAF1, E2F1, SF1, and ZNF143) were significantly highly expressed in the NAFLD patients with FDR < 0.05 and fold change > 1.8. This evidence concerns the gene ZBTB33 and metabolic dysfunction-associated steatotic liver disease.